CDC Updates Treatment Recommendations for Latent TB Infection

Share/Print
Posted Jun 28, 2018

The Centers for Disease Control and Prevention has updated the 2011 recommendations for use of once-weekly isoniazid-rifapentine for 12 weeks (3HP) for treatment of latent TB infection.

The  recommendations support and expand the use of an effective, yet shorter treatment regimen to reach more people with latent TB infection. The recommendations now include use of 3HP:

  • By directly observed therapy or self-administered therapy in people over 2 years of age
  • In people 2-11 years old
  • In persons with latent TB infection who are living with HIV/AIDS and taking antiretroviral medications with acceptable drug-drug interactions with rifapentine

Short course regimens, like 3HP, are preferred for reasons of convenience and higher rates of treatment completion. Treatment of latent TB infection is essential to controlling and eliminating TB in the United States because it substantially reduces the risk that latent TB infection will progress to TB disease.

Find the complete recommendations in the June 29 Morbidity and Mortality Weekly Report (MMWR) »

The CDC website also has new resources and tools for clinicians and patients: 

Clinician Resources

Patient Education Materials